{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:05:59Z","timestamp":1785769559536,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jaip.2020.05.016","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T22:20:13Z","timestamp":1590618013000},"page":"3141-3161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Symptomatic Dermographism: A Systematic Review of Treatment Options"],"prefix":"10.1016","volume":"8","author":[{"given":"Kanokvalai","family":"Kulthanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patompong","family":"Ungprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papapit","family":"Tuchinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Chularojanamontri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuda","family":"Rujitharanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungsima","family":"Kiratiwongwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuttagarn","family":"Jantanapornchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Hawro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.05.016_bib1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing, and management of chronic inducible urticarias\u2014The EAACI\/GA(2) LEN\/EDF\/UNEV consensus recommendations 2016 update and revision","volume":"71","author":"Magerl","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.016_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jaip.2018.03.007","article-title":"How to approach chronic inducible urticaria","volume":"6","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.05.016_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1468-3083.2005.01372.x","article-title":"Evaluation of patients with symptomatic dermographism","volume":"20","author":"Taskapan","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2020.05.016_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.iac.2013.09.010","article-title":"Physical urticarias and cholinergic urticaria","volume":"34","author":"Abajian","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2020.05.016_bib5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/jdv.12661","article-title":"Symptomatic dermographism: an inadequately described disease","volume":"29","author":"Schoepke","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2020.05.016_bib6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2340\/00015555-0240","article-title":"Urticaria: current opinions about etiology, diagnosis and therapy","volume":"87","author":"Zuberbier","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2020.05.016_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2133.1981.tb00043.x","article-title":"Factitious urticaria (dermographism): treatment by cimetidine and chlorpheniramine in a randomized double-blind study","volume":"104","author":"Kaur","year":"1981","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib8","first-page":"9","article-title":"Acrivastine versus terfenadine in the treatment of symptomatic dermographism\u2014a double blind, placebo-controlled study","volume":"17","author":"Boyle","year":"1989","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.jaip.2020.05.016_bib9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2133.1989.tb08195.x","article-title":"Symptomatic dermographism: wealing, mast cells and histamine are decreased in the skin following long-term application of a potent topical corticosteroid","volume":"121","author":"Lawlor","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2230.1989.tb00877.x","article-title":"The effect of psoralen photochemotherapy (PUVA) on symptomatic dermographism","volume":"14","author":"Logan","year":"1989","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib11","first-page":"60","article-title":"Narrow-band ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism","volume":"159","author":"Borzova","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2332\/allergolint.10-CR-0291","article-title":"Six cases of antihistamine-resistant dermographic urticaria treated with oral ciclosporin","volume":"60","author":"Toda","year":"2011","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2020.05.016_bib13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2230.1983.tb01814.x","article-title":"Symptomatic dermographism: natural history, clinical features laboratory investigations and response to therapy","volume":"8","author":"Breathnach","year":"1983","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib14","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1468-3083.2010.03951.x","article-title":"Physical urticaria: prevalence, type and natural course in a tropical country","volume":"25","author":"Silpa-Archa","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2020.05.016_bib15","first-page":"31","article-title":"Grading the response in dermographic urticaria","volume":"51","author":"Pasricha","year":"1985","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2020.05.016_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11882-017-0722-1","article-title":"Review of physical urticarias and testing methods","volume":"17","author":"Sanchez-Borges","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2020.05.016_bib17","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1111\/j.1365-2230.2008.03097.x","article-title":"Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg","volume":"34","author":"Magerl","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.016_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.1979.tb15293.x","article-title":"The effect of H1 and H2 histamine antagonists on symptomatic dermographism","volume":"101","author":"Matthews","year":"1979","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2133.1973.tb07548.x","article-title":"Dermographism: reduction in weal size by chlorpheniramine and hydroxyzine","volume":"88","author":"Matthews","year":"1973","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2340\/0001555563260262","article-title":"The effect of H1 and H2 receptor antagonists on the dermographic response","volume":"63","author":"Cook","year":"1983","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2020.05.016_bib22","first-page":"264","article-title":"Greater inhibition of dermographia with a combination of H1 and H2 antagonists","volume":"50","author":"Mansfield","year":"1983","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jaip.2020.05.016_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2133.1985.tb02319.x","article-title":"A\u00a0comparison of astemizole and chlorpheniramine in dermographic urticaria","volume":"112","author":"Krause","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000248580","article-title":"Calcium antagonist in the treatment of symptomatic dermographism. Low-dose and high-dose studies with nifedipine","volume":"177","author":"Lawlor","year":"1988","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaip.2020.05.016_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2133.1993.tb00488.x","article-title":"The effect of cetirizine on symptoms and wealing in dermographic urticaria","volume":"129","author":"Sharpe","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2133.1993.tb00487.x","article-title":"In dermographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone","volume":"129","author":"Sharpe","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib27","first-page":"251","article-title":"Ketotifen in the treatment of symptomatic dermographism","volume":"60","author":"Daniel","year":"1994","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2020.05.016_bib28","first-page":"325","article-title":"Combined treatment with pizotifen and cinnarizin in urticaria factitia","volume":"62","author":"Toth-Kasa","year":"1987","journal-title":"Z\u00a0Hautkr"},{"key":"10.1016\/j.jaip.2020.05.016_bib29","first-page":"509","article-title":"The effect of ketotifen in urticaria factitia and cholinergic urticaria in a double-blind crossover study","volume":"36","author":"Cap","year":"1985","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaip.2020.05.016_bib30","first-page":"78","article-title":"Desloratadine in the treatment of physical urticaria: study on efficacy and safety in dermographic, pressure and heat urticaria","volume":"57","author":"Ayala","year":"2003","journal-title":"Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale"},{"key":"10.1016\/j.jaip.2020.05.016_bib31","first-page":"88","article-title":"Efficacy of H1, antihistamine, corticosteroids and cyclophosphamide in the treatment of chronic dermographic urticaria","volume":"68","author":"Kumar","year":"2002","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2020.05.016_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.jaip.2020.05.016_bib33","first-page":"185","article-title":"Omalizumab is effective and safe in symptomatic dermographism: results of UFO, a multicentre randomized, placebo-controlled trial","volume":"71","author":"Metz","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.016_bib34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.05.016_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2020.05.016_bib36","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2020.05.016_bib37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.jaip.2020.05.016_bib38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaip.2020.05.016_bib39","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0002-9149(97)00634-6","article-title":"Electrocardiographic findings in patients with diphenhydramine overdose","volume":"80","author":"Zareba","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaip.2020.05.016_bib40","first-page":"79","article-title":"Rare complications of diphenhydramine toxicity","volume":"72","author":"Ramachandran","year":"2008","journal-title":"Conn Med"},{"key":"10.1016\/j.jaip.2020.05.016_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","article-title":"Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper","volume":"65","author":"Church","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.016_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","article-title":"Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence","volume":"28","author":"Collamati","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.jaip.2020.05.016_bib43","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/all.12901","article-title":"Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence","volume":"71","author":"Maurer","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.016_bib44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/all.12870","article-title":"Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial","volume":"71","author":"Staubach","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.016_bib45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.05.016_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ajd.12406","article-title":"Cyclophosphamide in dermatology","volume":"58","author":"Kim","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaip.2020.05.016_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jdv.15720","article-title":"Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism","volume":"33","author":"Bergmann","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2020.05.016_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.anai.2019.08.014","article-title":"New treatments for chronic urticaria","volume":"124","author":"Kolkhir","year":"2020","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820305080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820305080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:26:34Z","timestamp":1761974794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820305080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2213219820305080"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.05.016","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptomatic Dermographism: A Systematic Review of Treatment Options","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}